Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 352

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 352
---
 13, 2024,
which represents the date the consolidated financial statements were issued, for events requiring recognition or disclosure in the consolidated
financial statements for the year ended December 31, 2024. The Company concluded that no events have occurred that would require recognition
or disclosure in the consolidated financial statements, except for the January 2025 Offering that was completed on January 16, 2025,
as described in Note 6(e) and for the SEPA that was entered with Yorkville on February 12, 2025, as described in Note 6(f).

F-17

Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

Item
9A. Controls and Procedures. Disclosure Controls and Procedures.

Limitations
on Effectiveness of Controls and Procedures

In
designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how
well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design
of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply
judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Evaluation
of Disclosure Controls and Procedures

Our
management, with the participation of our principal executive officer and principal financial officer, evaluated, as of December 31,
2024, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act).
Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and
procedures were effective at the reasonable assurance level as of December 31, 2024.

Management’s
Annual Report on Internal Control over Financial Reporting

Our
management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined
in Rule 13a-15(f) under the Exchange Act.

Our
management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth
in “Internal Control- Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on our assessment, our management concluded that as of December 31, 2024, our internal control over financial reporting was effective.

71

Attestation
Report of the Independent Registered Public Accounting Firm

This
Annual Report does not include